Skip to content

Wholebody MRI In Lung Cancer StagiNg

Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02716051
Acronym
WISLON
Enrollment
36
Registered
2016-03-23
Start date
2016-03-31
Completion date
2019-06-30
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

Magnetic Resonnace Imaging (MRI) and Positron Emission Tomography (PET) can be both used in detection of nodes in patients with cell lung cancer (NSCLC). However, the cardiorespiratory synchronization in the MRI, allowing acquisition of synchronous images with breathing and heart movements should increase the sensitivity of detection of pathologic mediastinal lymph nodes. Given its high sensitivity, whole-body MRI with diffusion could possibly be at least as informative as PET, while being less expensive, not radiant. The purpose of this study is to evaluate the performance of whole-body MRI with diffusion with cardiorespiratory synchronization, on the detection of mediastinal nodes (which are known to be less well detected by MRI) compared to PET.

Interventions

DEVICEMRI

Whole body MRI with cardiac and pulmonary synchronization

DEVICEPET

Sponsors

University Hospital, Limoges
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years, * Neoplasia bronchopulmonary (SCLC and NSCLC) newly diagnosed, * Patient potentially eligible for curative treatment, but no no treatment started, * Patients for whom a PET scan and MRI are planned Non Inclusion Criteria: * claustrophobia, * Implantable Medical Device * not compatible pacemaker type or heart valve, metal splinters eye) * Pregnant or lactating women,

Design outcomes

Primary

MeasureTime frameDescription
Th consistency of the locations of mediastinal lesionsDay 1Node localization according to MRI and PET scan measurements on the same day

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026